EIF2AK3 and leukemia: Sorafenib (Nexavar®), an Raf1/Mek/Erk kinase inhibitor approved for advanced hepatocarcinoma cells (HCC) [35], was recently shown to induce an ER stress characterised by the activation of PERK-phosphorylation of eIF2α axis in leukemia cells [36].